Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (501-510 of 674) with videos related to

Pageof 68
Sort By:
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Research Square|September 2, 2025
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program to Improve the Functioning of Persons Suffering from Post-acute Sequelae of SARS-CoV-2 infection (PASC): A Randomized Controlled TrialMd Benjamin Abramoff, Md Timothy Dillingham, Ma Ms Ava-Kathleen Rybicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)Hope S Rugo, William T Barry, Alvaro Moreno-Aspitia, et al.
Nature|June 10, 2011
A genetically humanized mouse model for hepatitis C virus infectionMarcus Dorner, Joshua A Horwitz, Justin B Robbins, et al.
British Journal of Cancer|February 23, 2024
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancerCath Eberlein, Stuart C Williamson, Lorna Hopcroft, et al.
Journal of the National Cancer Institute|September 21, 2010
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancerXinhui Wang, Takuya Osada, Yangyang Wang, et al.
Theranostics|March 10, 2022
Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distributionNicole Strittmatter, Jennifer I Moss, Alan M Race, et al.
Molecular Cancer Therapeutics|August 12, 2018
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null TumorsJames T Lynch, Urszula M Polanska, Ursula Hancox, et al.
Journal of Medicinal Chemistry|January 22, 2005
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugsPhilip Reigan, Philip N Edwards, Abdul Gbaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcomeWilliam T Barry, Dawn N Kernagis, Holly K Dressman, et al.
Pageof 68

Showing results (501-510 of 674) with videos related to

Sort By:
Pageof 68
Plos One|July 11, 2013
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibJames R Bradford, Matthew Farren, Steve J Powell, et al.
Research Square|September 2, 2025
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program to Improve the Functioning of Persons Suffering from Post-acute Sequelae of SARS-CoV-2 infection (PASC): A Randomized Controlled TrialMd Benjamin Abramoff, Md Timothy Dillingham, Ma Ms Ava-Kathleen Rybicki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)Hope S Rugo, William T Barry, Alvaro Moreno-Aspitia, et al.
Nature|June 10, 2011
A genetically humanized mouse model for hepatitis C virus infectionMarcus Dorner, Joshua A Horwitz, Justin B Robbins, et al.
British Journal of Cancer|February 23, 2024
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancerCath Eberlein, Stuart C Williamson, Lorna Hopcroft, et al.
Journal of the National Cancer Institute|September 21, 2010
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancerXinhui Wang, Takuya Osada, Yangyang Wang, et al.
Theranostics|March 10, 2022
Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distributionNicole Strittmatter, Jennifer I Moss, Alan M Race, et al.
Molecular Cancer Therapeutics|August 12, 2018
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null TumorsJames T Lynch, Urszula M Polanska, Ursula Hancox, et al.
Journal of Medicinal Chemistry|January 22, 2005
Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugsPhilip Reigan, Philip N Edwards, Abdul Gbaj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcomeWilliam T Barry, Dawn N Kernagis, Holly K Dressman, et al.
Pageof 68